Abstract:ABSTRACT Accumulating evidence implicates gut microbiota as promising targets for the treatment of type 2 diabetes mellitus (T2DM). With a randomized clinical trial, we tested the hypothesis that alteration of gut microbiota may be involved in the alleviation of T2DM with hyperlipidemia by metformin and a specifically designed herbal formula (AMC). Four hundred fifty patients with T2DM and hyperlipidemia were randomly assigned to either the metformin- or AMC-treated group. After 12 weeks of treatment, 100 patients were randomly selected from each group and assessed for clinical improvement. The effects of the two drugs on the intestinal microbiota were evaluated by analyzing the V3 and V4 regions of the 16S rRNA gene by Illumina sequencing and multivariate statistical methods. Both metformin and AMC significantly alleviated hyperglycemia and hyperlipidemia and shifted gut microbiota structure in diabetic patients. They significantly increased a coabundant group represented by Blautia spp., which significantly correlated with the improvements in glucose and lipid homeostasis. However, AMC showed better efficacies in improving homeostasis model assessment of insulin resistance (HOMA-IR) and plasma triglyceride and also exerted a larger effect on gut microbiota. Furthermore, only AMC increased the coabundant group represented by Faecalibacterium spp., which was previously reported to be associated with the alleviation of T2DM in a randomized clinical trial. Metformin and the Chinese herbal formula may ameliorate type 2 diabetes with hyperlipidemia via enriching beneficial bacteria, such as Blautia and Faecalibacterium spp. IMPORTANCE Metabolic diseases such as T2DM and obesity have become a worldwide public health threat. Accumulating evidence indicates that gut microbiota can causatively arouse metabolic diseases, and thus the gut microbiota serves as a promising target for disease control. In this study, we evaluated the role of gut microbiota during improvements in hyperglycemia and hyperlipidemia by two drugs: metformin and a specifically designed Chinese herbal formula (AMC) for diabetic patients with hyperlipidemia. Both drugs significantly ameliorated blood glucose and lipid levels and shifted the gut microbiota. Blautia spp. were identified as being associated with improvements in glucose and lipid homeostasis for both drugs. AMC exerted larger effects on the gut microbiota together with better efficacies in improving HOMA-IR and plasma triglyceride levels, which were associated with the enrichment of Faecalibacterium spp. In brief, these data suggest that gut microbiota might be involved in the alleviation of diabetes with hyperlipidemia by metformin and the AMC herbal formula.

White Common Bean Extract Remodels the Gut Microbiota and Ameliorates Type 2 Diabetes and Its Complications: A Randomized Double-Blinded Placebo-Controlled Trial

Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2 Diabetes.

White Hyacinth Bean Polysaccharide Ameliorates Diabetes Via Microbiota-Gut-brain Axis in Type 2 Diabetes Mellitus Rats.

Effects of Lipid Extract from Blue Mussel (mytilus Edulis) on Gut Microbiota, and Its Relationship with Glycemic Traits in Type 2 Diabetes Mellitus Patients: a Double-Blind Randomized Controlled Trial

Lipid Extract from Blue Mussel (mytilus Edulis) Improves Glycemic Traits in Chinese Type 2 Diabetic Mellitus Patients: a Double-Blind Randomized Controlled Trial

Structural Alteration of Gut Microbiota During the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial

Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites

Dietary Compounds and Traditional Chinese Medicine Ameliorate Type 2 Diabetes by Modulating Gut Microbiota

Effect of Jianpi Qinghua Decoction on Gut Microbiota, Intestinal Permeability and Glycolipid Metabolism in Newly Diagnosed T2DM Patients: Study Protocol for a Randomized, Double-blind, Placebo-controlled Clinical Trial

Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications

Health Improvements of Type 2 Diabetic Patients Through Diet and Diet Plus Fecal Microbiota Transplantation

The Potential Mechanism of Liu–Wei–Di–Huang Pills in Treatment of Type 2 Diabetic Mellitus: from Gut Microbiota to Short-Chain Fatty Acids Metabolism

Black bean husk and black rice anthocyanin extracts modulated gut microbiota and serum metabolites for improvement in type 2 diabetic rats.

Efficacy and Mechanism of the Jiangtang Tiaozhi Recipe in the Management of Type 2 Diabetes and Dyslipidaemia: A Clinical Trial Protocol

Hypoglycemic effects of white hyacinth bean polysaccharide on type 2 diabetes mellitus rats involvement with entero-insular axis and GLP-1 via metabolomics study

Polysaccharides from small black soybean alleviating type 2 diabetes via modulation of gut microbiota and serum metabolism

Effect of "maccog" TCM tea on improving glucolipid metabolism and gut microbiota in patients with type 2 diabetes in community

Effect of RG (Coptis root and ginseng) formula in patients with type 2 diabetes mellitus: a study protocol for a randomized controlled and double-blinding trial

Gut modulation based anti-diabetic effects of carboxymethylated wheat bran dietary fiber in high-fat diet/streptozotocin-induced diabetic mice and their potential mechanisms

Double-blinded, Randomized Clinical Trial of Gegen Qinlian Decoction Pinpoints Faecalibacterium as Key Gut Bacteria in Alleviating Hyperglycemia

Gut microbiota mediate the alleviation effect of Xiehuo-Guzheng granules on β cell dedifferentiation in type 2 diabetes mellitus